Novavax Inc. stock surged June 5 after the company said it is in collaboration with the National Institutes of Health to evaluate a potential H1N1 vaccine. The company announced that its scientists produced a virus-like particle in May that is similar in size and structure to particles of the H1N1 virus, but they don"t have the genes needed to replicate. Novavax developed the particle to provoke an immune response against the H1N1 virus in the human body. The company is working with the Division of Microbiology and Infectious Disease, which is part of the National Institute of Allergy and Infectious Diseases.